Document Type
Article
Publication Date
3-1-2025
Abstract
This review discusses the differing effects of enzyme-inducing and non-inducing antiseizure medications on cardiovascular risk and their implications for the management strategies of epilepsy patients. Traditional risk markers, including low density lipoprotein, high density lipoprotein and triglycerides, can be altered by both enzyme induction and inhibition. Other markers of vascular risk, including c-reactive protein, non-high-density lipoprotein and homocysteine, are affected by antiseizure medications, although adults and children may have different responses. The overall atherosclerotic risk picture is more complex due to indirect effects such as neuroendocrine function and the metabolic syndrome. Large scale data shows an evolving understanding of cardiovascular risk. Long term risks of enzyme inducing antiseizure medications and valproic acid are apparent when studies examine medications individually. Finally, effects of antiseizure medications on cardiac rhythm and possibly autonomic control are discussed with respect to their clinical relevance to the practicing clinician.
Recommended Citation
Abbasi, Aleena; Abbasi, Bassil; Mintzer, Scott; and LoPinto-Khoury, Carla, "Antiseizure Medications and Their Differing Effects on Cardiovascular Risk" (2025). Department of Neurology Faculty Papers. Paper 355.
https://jdc.jefferson.edu/neurologyfp/355
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
PubMed ID
40007616
Language
English
Included in
Epidemiology Commons, Investigative Techniques Commons, Neurology Commons, Pharmacology Commons
Comments
This article is the author's final published version in Epilepsy and Behavior Reports, Volume 29, 2025, Article number 100746.
The published version is available at https://doi.org/10.1016/j.ebr.2025.100746.
Copyright © 2025 The Author(s)